Roivant (ROIV) president exercises options, sells 200K shares on Form 4

Rhea-AI Filing Summary

Roivant Sciences Ltd. executive Eric Venker, President & Immunovant CEO, reported an option exercise and share sale. On January 12, 2026, he exercised stock options covering 200,000 Common Shares at an exercise price of $3.85 per share. That same day, he sold 200,000 Common Shares at a weighted average price of $21.92 per share, with individual sale prices ranging from $21.59 to $22.20.

After these transactions, Venker directly held 1,654,597 Common Shares and 5,244,834 stock options representing rights to buy additional Common Shares. The option award originally began vesting on April 20, 2022, with 25% vesting after one year and the remainder vesting in 36 equal monthly installments, subject to his continued service.

Insider Trade Summary

Net Seller: 200,000 shares ($4,384,000)

Net Sell 3 txns

Insider Venker Eric

Role President & Immunovant CEO

Sold 200,000 shs ($4.38M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	200,000	$0.00	--
Exercise	Common Shares	200,000	$3.85	$770K
Sale	Common Shares	200,000	$21.92	$4.38M

Holdings After Transaction: Stock Option (Right to Buy) — 5,244,834 shares (Direct); Common Shares — 1,854,597 shares (Direct)

Footnotes (1)

1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.59 to $22.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Venker Eric

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON X0 SW1H 0DB

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & Immunovant CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	01/12/2026		M		200,000	A	$3.85	1,854,597	D
Common Shares	01/12/2026		S		200,000	D	$21.92(1)	1,654,597	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.85	01/12/2026		M			200,000	(2)	04/19/2032	Common Stock	200,000	$0	5,244,834	D

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.59 to $22.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

2. Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

	By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker	01/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ROIV executive Eric Venker report on this Form 4?

Eric Venker reported three transactions on January 12, 2026: (1) the exercise of a stock option for 200,000 Common Shares at $3.85 per share, and (2) and (3) matching non-derivative entries showing the acquisition of 200,000 Common Shares from the option exercise and the sale of 200,000 Common Shares at a weighted average price of $21.92 per share.

How many Roivant Sciences (ROIV) shares does Eric Venker own after this Form 4?

Following the reported transactions, Eric Venker directly owned 1,654,597 Common Shares of Roivant Sciences Ltd. and held 5,244,834 stock options (stock options with a right to buy Common Shares).

At what prices did the Roivant (ROIV) insider transactions occur?

The stock option had an exercise price of $3.85 per share. The sale of 200,000 Common Shares was reported at a weighted average price of $21.92 per share, with individual sale prices ranging from $21.59 to $22.20.

What is Eric Venker’s role at Roivant Sciences Ltd. (ROIV)?

Eric Venker is an officer of Roivant Sciences Ltd., serving as President & Immunovant CEO, according to the Form 4 disclosure.

How do the reported Roivant (ROIV) stock options vest for Eric Venker?

The stock options to purchase Common Shares have a vesting commencement date of April 20, 2022. They vest and become exercisable 25% on the first anniversary of that date and then in 36 equal monthly installments thereafter, subject to his continuous service, unless otherwise provided in the award documentation.

What does the weighted average sale price mean in this Roivant (ROIV) Form 4?

The Form 4 explains that the $21.92 price is a weighted average for multiple trades. The 200,000 Common Shares were sold in separate transactions at prices ranging from $21.59 to $22.20, and detailed trade information is available upon request from the issuer, its security holders, or SEC staff.